Sakar Healthcare financials

·UnclassifiedChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹87.4cr+51.9% on Q2 FY26
Net profit
₹11.3cr+149.1% on Q2 FY26
EBITDA margin
27.9%+8.1 pts on Q2 FY26
EPS
₹5.08+150.2% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue87.457.6+51.9%
EBITDA24.311.4+114.4%
EBITDA margin27.9%19.7%+8.1 pts
Profit before tax16.05.4+199.0%
Net profit11.34.5+149.1%
EPS₹5.08₹2.03+150.2%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹87.4 crNet profit₹11.3 crNet margin12.9%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,106————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.050.10.10.33.5
55.355.375.068.8111
2,161————
302252178153133
—+41.8%+15.8%+15.0%—
90.468.949.738.433.1
30.0%27.4%28.0%25.0%24.9%
65.045.328.820.318.2
42.930.517.511.712.8
14.2%12.1%9.9%7.6%9.6%
₹19.27₹13.70₹7.87₹5.25₹5.73
—+74.2%+50.0%−8.5%—
—49.335.624.533.3
—0.0−32.3−59.6−82.2
49.349.33.3−35.1−48.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SAKAR₹946.50

Sakar Healthcare Limited

· Unclassified
₹ CrorePeersMACPOWERSERVOTECHKAPSTONTHEJOBETAMcap ₹2,106 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————2,106.0
- Cash, Equiv & ST Investments3.50.30.150.10.0
+ Total Debt111.268.875.055.355.3
Enterprise Value————2,161.2
Revenue133.4153.4177.6251.7301.8
Growth %, YoY—+15.0+15.8+41.8—
EBITDA33.138.449.768.990.4
Margin %24.8525.0227.9827.3729.96
EBIT18.220.328.845.365.0
Net Income12.811.717.530.542.9
Margin %9.577.619.8612.1114.20
EPS, Adj (current shares)5.735.257.8713.7019.27
Growth %, YoY—-8.5+50.0+74.2—
Cash from Operations33.324.535.649.3—
Capital Expenditures-82.2-59.6-32.3-0.0—
Free Cash Flow-48.9-35.13.349.349.3
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Sakar Healthcare financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

Sakar Healthcare (NSE: SAKAR) had a market capitalisation of ₹2,106 crore at the previous close (₹946.50 a share), a PE ratio of 49.1 on the last four quarters' profit and a price-to-book ratio of 6.09. In FY26 its consolidated net profit was ₹30.5 crore on revenue of ₹252 crore; in Q2 FY27 (July–September 2026) it was ₹11.3 crore, up 149.1% year on year. Its debt-to-equity ratio was 0.13 on 30 September 2026. Promoters held 51.70% of the shares on 30 September 2026.

Share price used
₹946.50 · previous close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Sakar Healthcare at a glance · consolidated

Market cap
₹2,106 Crat ₹946.50 · previous close
PE ratio (last 4 quarters)
49.169.1 on FY26 profit
Price to book (PB)
6.09book value ₹155.50 a share
ROE (FY26)
10.0%+3.6 pts vs FY25ROCE 12.5%
Debt to equity
0.13net debt ₹45.8 Cr
Promoter holding
51.70%−0.8 pts vs 30 Jun 202630 September 2026
Net worth
₹346 Cr+14.1% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹49.3 Cr
EPS (FY26)
₹13.70

Questions

What is the Sakar Healthcare PE ratio today?

Sakar Healthcare's PE ratio is 49.1 at the previous close (₹946.50 a share): a market capitalisation of ₹2,106 crore divided by consolidated net profit of ₹42.9 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹30.5 crore) it is 69.1.

What is the Sakar Healthcare debt to equity ratio?

Sakar Healthcare's debt-to-equity ratio was 0.13 on 30 September 2026: borrowings of ₹46 crore against total equity of ₹346 crore. A year earlier, on 30 September 2025, it was 0.24.

What is the Sakar Healthcare net worth?

Sakar Healthcare's net worth — shareholders' equity in its consolidated balance sheet — was ₹346 crore on 30 September 2026, up 14.1% from ₹303 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,106 crore at the previous close.

What is the Sakar Healthcare PB ratio (price to book value)?

Sakar Healthcare's price-to-book (PB) ratio is 6.09 at the previous close: a market capitalisation of ₹2,106 crore divided by shareholders' equity (book value) of ₹346 crore on 30 September 2026. That is a book value of ₹155.50 per share against a share price of ₹946.50.

What is the Sakar Healthcare ROE and ROCE?

In FY26, Sakar Healthcare's return on equity (ROE) was 10.0% and its return on capital employed (ROCE) was 12.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 6.4% and ROCE 8.5%.

What is the Sakar Healthcare book value per share?

Sakar Healthcare's book value per share was ₹155.50 on 30 September 2026: shareholders' equity of ₹346 crore divided by the 2.22 crore shares in issue, up 14.1% from ₹136.29 a year earlier. The share price at the previous close was ₹946.50.

What is the Sakar Healthcare market cap?

Sakar Healthcare's market capitalisation was ₹2,106 crore at the previous close: 2.22 crore shares at ₹946.50 each.

Is Sakar Healthcare debt free?

No. Sakar Healthcare had borrowings of ₹46 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.13. Its cash and current investments were ₹27 lakh, so its net debt was ₹45.8 crore.

What is the Sakar Healthcare EPS?

Sakar Healthcare's basic earnings per share (EPS) were ₹13.70 in FY26, against ₹7.97 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹19.25.

What is the Sakar Healthcare promoter holding?

Promoters held 51.70% of Sakar Healthcare on 30 September 2026, down 0.82 percentage points from 52.52% the previous quarter and down 1.16 percentage points from 52.86% a year earlier, according to the shareholding pattern filed with NSE.

What is the Sakar Healthcare free cash flow?

In FY26, Sakar Healthcare generated ₹49.3 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹49.3 crore. In FY25 it was ₹3.3 crore.

When are the Sakar Healthcare next results?

Sakar Healthcare has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

What is the Sakar Healthcare shareholding pattern?

On 30 September 2026, Sakar Healthcare's shares were held by promoters 51.70%, foreign portfolio investors (FII/FPI) 12.34%, domestic institutions (DII) 11.92% and retail and other non-institutional investors 24.04%. Over the year, FII holding was down 0.97 percentage points from 13.31% and DII holding was up 0.49 percentage points from 11.43%.

How does Sakar Healthcare compare with its peers?

On FY26 consolidated figures, against Macpower CNC Machines: Sakar Healthcare's operating margin of 18.0% is the higher of the two (Macpower CNC Machines 14.0%; peer average 14.0%); its return on equity of 10.0% is the lower of the two (Macpower CNC Machines 21.3%; peer average 21.3%); its revenue growth over three years of 23.6% a year is the higher of the two (Macpower CNC Machines 18.2% a year; peer average 18.2% a year).

Sakar Healthcare vs Macpower CNC Machines: how do they compare?

In FY26, Sakar Healthcare earned net profit of ₹30.5 crore on revenue of ₹252 crore, against ₹33.9 crore on ₹333 crore for Macpower CNC Machines. Sakar Healthcare's operating margin was 18.0% (Macpower CNC Machines 14.0%) and its return on equity 10.0% (Macpower CNC Machines 21.3%).

What are the Sakar Healthcare latest quarterly results?

Sakar Healthcare's latest results are for Q2 FY27 (July–September 2026), filed on 23 October 2026: consolidated net profit ₹11.3 crore, up 149.1% from ₹4.5 crore in Q2 FY26; revenue from operations ₹87.4 crore, up 51.9% year on year.

What is the Sakar Healthcare revenue and profit in FY26?

In FY26 (April 2025–March 2026), Sakar Healthcare's consolidated net profit was ₹30.5 crore, up 74.2% from ₹17.5 crore in FY25, on revenue from operations of ₹252 crore (up 41.8%). Over three years, from FY23, net profit was up 138.9%.

Where do these Sakar Healthcare figures come from?

From Sakar Healthcare's own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.